Provided by Tiger Fintech (Singapore) Pte. Ltd.

Lineage Cell Therapeutics Inc

0.4983
+0.02635.57%
Post-market: 0.4969-0.0014-0.28%16:55 EDT
Volume:1.32M
Turnover:630.26K
Market Cap:113.79M
PE:-5.36
High:0.4989
Open:0.4688
Low:0.4609
Close:0.4720
Loading ...

Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 3rd Annual Spinal Cord Injury Investor Symposium

Business Wire
·
22 Apr

Lineage to Present at 2025 Eyecelerator Meeting Sponsored by the American Academy of Ophthalmology (AAO)

Business Wire
·
21 Apr

Maxim Group Reaffirms Their Buy Rating on Lineage Therap (LCTX)

TIPRANKS
·
05 Apr

Lineage Cell Therapeutics Is Maintained at Buy by B. Riley Securities

Dow Jones
·
14 Mar

B. Riley Cuts Price Target on Lineage Cell Therapeutics to $3 From $4, Keeps Buy Rating

MT Newswires Live
·
14 Mar

Lineage Cell Therapeutics Faces Uncertainty Amid New U.S. Administration’s Policies

TIPRANKS
·
12 Mar

Q4 2024 Lineage Cell Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents
·
11 Mar

Lineage Cell Therapeutics Is Maintained at Buy by D. Boral Capital

Dow Jones
·
11 Mar

Lineage Cell Therapeutics Inc (LCTX) Q4 2024 Earnings Call Highlights: Strategic Advances and ...

GuruFocus.com
·
11 Mar

Lineage Cell (LCTX) Reports Q4 Loss, Tops Revenue Estimates

Zacks
·
11 Mar

Lineage Cell Therapeutics Inc - Q4 Revenue Around $2.9 Million

THOMSON REUTERS
·
11 Mar

Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Business Wire
·
11 Mar

Zymeworks Inc. (ZYME) Reports Q4 Loss, Misses Revenue Estimates

Zacks
·
06 Mar

Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on March 10, 2025

Business Wire
·
05 Mar

Lineage Cell Therapeutics Price Target Maintained With a $9.00/Share by HC Wainwright & Co.

Dow Jones
·
12 Feb

Lineage Cell Therapeutics Begins Stem Cell Therapy Trial for Spinal Cord Injury

MT Newswires Live
·
11 Feb

Lineage Cell Therapeutics Is Maintained at Buy by D. Boral Capital

Dow Jones
·
11 Feb

BRIEF-Lineage Initiates Clinical Study Of OPC1 For Spinal Cord Injury

Reuters
·
11 Feb

Lineage Initiates Clinical Study of Opc1 for Spinal Cord Injury

THOMSON REUTERS
·
11 Feb

Lineage Cell (LCTX) Upgraded to Strong Buy: What Does It Mean for the Stock?

Zacks
·
31 Jan